Insulin-like Growth Factors in a clinical setting: Review of IGF-I

Fryšák, Zdeněk; Schovánek, Jan; Iacobone, Maurizio; Karásek, David

doi:10.5507/bp.2015.041

Cited by 26 publications

(21 citation statements)

References 51 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It influences growth and differentiation processes (Frysak et al 2015). IGF-1 has been designated as a potential therapeutic target for neurodegenerative diseases such as MDD (Szczesny et al 2013).…”

Section: Neurotrophins and Other Growth Factorsmentioning

confidence: 99%

“…Insulin-like growth factor (IGF-1) and its receptor IGF-1R are found in many tissues including the brain (Aberg et al 2006 ). It influences growth and differentiation processes (Frysak et al 2015 ). IGF-1 has been designated as a potential therapeutic target for neurodegenerative diseases such as MDD (Szczesny et al 2013 ).…”

Section: Neurotrophins and Other Growth Factorsmentioning

confidence: 99%

See 1 more Smart Citation

Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression

et al. 2018

View full text Add to dashboard Cite

Depression is a major health problem with a high prevalence and a heavy socioeconomic burden in western societies. It is associated with atrophy and impaired functioning of cortico-limbic regions involved in mood and emotion regulation. It has been suggested that alterations in neurotrophins underlie impaired neuroplasticity, which may be causally related to the development and course of depression. Accordingly, mounting evidence suggests that antidepressant treatment may exert its beneficial effects by enhancing trophic signaling on neuronal and synaptic plasticity. However, current antidepressants still show a delayed onset of action, as well as lack of efficacy. Hence, a deeper understanding of the molecular and cellular mechanisms involved in the pathophysiology of depression, as well as in the action of antidepressants, might provide further insight to drive the development of novel fast-acting and more effective therapies. Here, we summarize the current literature on the involvement of neurotrophic factors in the pathophysiology and treatment of depression. Further, we advocate that future development of antidepressants should be based on the neurotrophin theory.

show abstract

Section: Neurotrophins and Other Growth Factorsmentioning

confidence: 99%

Section: Neurotrophins and Other Growth Factorsmentioning

confidence: 99%

Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression

et al. 2018

View full text Add to dashboard Cite

show abstract

“…IGF mRNAs have been detected in several target tissues, and at the same time both IGF types exert a negative feedback at the hypothalamic level maintaining basal steady levels of GH (1). Both circulating and local bioavailability is regulated by high affinity binding proteins which fine-tune their local action (5).…”

Section: Introductionmentioning

confidence: 99%

Growth Hormone and Reproduction: Lessons Learned From Animal Models and Clinical Trials

et al. 2019

View full text Add to dashboard Cite

Growth Hormone (GH) has been considered as a therapeutic option to increase the number of growing follicles during Assisted Reproductive Technology (ART) for more than 30 years. In this review the biological rationale for therapeutic GH usage is explained through evidence in animal models, aiming to put this into a clinical context. First, we explain the GH—Insulin like Growth Factor (IGF)-1—gonadal axis and its role in reproduction. Evidence suggests that GH can stimulate the secretion of IGF1 not only in the liver but also in the peripheral target structures, including the ovary. Moreover, IGF-1 can be secreted locally under the influence of stimuli other than GH. In the case of the ovary, steroid hormones, gonadotropins or the combination of both seems to be involved. Even more interesting, the ovary itself can secret GH locally and exert a paracrine action modulating the intracellular signaling pathway of GH, i.e., not by the systemic pathway where GH binds to the extracellular domain of the GH receptor. Finally, these aspects from animal models are put into clinical perspective by discussing results and shortcomings of studies and meta-analyses in order to put forth the state-of-the-art rationale for therapeutic GH usage in modern ART.

show abstract

“…У тканинах практично вся дія соматотропного гормону забезпечується ІФР. З печінки соматомедин потрапляє в кровотік, а звідти, завдяки посередництву протеїнівпереносників, в тканини й органи (Frysaka et al, 2015).…”

Section: вступunclassified

The concentration of insuline-like growth factor in colostrum, milk and plasma of cows

2019

View full text Add to dashboard Cite

Recently, a significant amount of data has been reported indicating on the link between consumption of dairy products and development of oncological diseases. This could be explained by the presence in milk of various hormones, particularly insulin-like growth factor (IGF). This hormone is a mediator between somatotropin and tissues. In response to the increase of the blood level of growth hormone, hepatocytes begin actively synthesize the IGF, which accelerates the rate of the metabolism, including those of onco-cells. The majority of studies relate to humane medicine, and data on the dependence of IGF milk levels on breed, period of lactation, diet, physiological, and clinical status of an animal are lacking. Taking this into consideration, the purpose of this study was to analyze the concentration of insulin-like factor in colostrum, milk of cows and blood plasma at various stages of lactation. Study was performed on cows of Ukrainian blackand-white dairy breed in their from second to fifth lactation with milk yield 5100-5700 kg per previous lactation. Concentration of IGF was detected in colostrum, milk and plasma of cows, using enzyme immunoassay. Obtained material gives evidence that the highest IGF level is present in colostrum. After that hormone concentration decreases up to 10-14 day of lactation. High level of IGF in colostrum might be associated with necessity to stimulate metabolism of calves in early postnatal period of ontogenesis. Immediately after calving plasma level of IGF decreases. The highest level was observed on 10-14 th days of lactation. Taking into consideration physiological function of the given hormone, there is no univocal explanation of the decrease of its plasma level in cows at the beginning of lactation. This could be associated with energy deficit, physiological condition of animals or with developing of lactation dominant and levels of other hormones. Potential of further research lies in investigation of the dependence of the IGF level in the secretion of the mammary gland on productivity, breed, age and diet of animals.

show abstract

Insulin-like Growth Factors in a clinical setting: Review of IGF-I

Cited by 26 publications

References 51 publications

Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression

Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression

Growth Hormone and Reproduction: Lessons Learned From Animal Models and Clinical Trials

The concentration of insuline-like growth factor in colostrum, milk and plasma of cows

Contact Info

Product

Resources

About